IGC subsidiary licenses NMI compounds from JNCASR for Alzheimer's treatment

IGC Pharma, Inc.

Hamsa Biopharma (IGC subsidiary) obtains exclusive worldwide license for NMI Compounds from JNCASR.
NMI Compounds are small molecule inhibitors that may reduce amyloid neurotoxicity, targeting Alzheimer's and other CNS disorders.
License fee of INR [***] with milestone payment upon FDA Phase II approval; royalties of [***]% of Net Revenue.
IGC gains rights to prosecute patents, use all licensor technology, and first refusal on future CNS inventions.
Agreement includes sublicensing rights and term until last patent expiration.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.